AI Analysis
AI-generated analysis. Always verify with the original filing.
GSK plc, Pfizer, and Shionogi completed a transaction on April 1, 2026, resulting in Pfizer's exit from ViiV Healthcare and an increase in Shionogi's economic interest to 21.7%, with GSK maintaining a 78.3% majority share.
Key Takeaways
1Pfizer exited its 11.7% economic interest in ViiV Healthcare, receiving $1.875 billion from the transaction.
2Shionogi increased its economic interest in ViiV Healthcare to 21.7% by purchasing new shares for $2.125 billion.
3GSK maintained its 78.3% majority economic interest in ViiV Healthcare and received a special dividend of $0.250 billion.
4The Pfizer put option liability in GSK's accounts for the year ended December 31, 2025, was extinguished through retained earnings at completion.